Search research articles
Contact Us
Filters
Showing results (501-510 of 713) with videos related to
Page
of 72
Sort By:
American Journal of Hematology
|
December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma
|
March 27, 2019
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis
Jesus G Berdeja, Michael C Heinrich, Shaker R Dakhil, et al.
British Journal of Haematology
|
December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Stéphane De Botton, Christian Récher, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 21, 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis
James Foran, Farhad Ravandi, William Wierda, et al.
Cancer
|
December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
Susan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood
|
March 17, 2012
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
Farhad Ravandi, Eli Estey, Dan Jones, et al.
Blood
|
August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Deborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.
Cancer
|
December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
William Wierda, Susan O'brien, Stefan Faderl, et al.
American Journal of Hematology
|
October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors
Ahmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.
Page
of 72
Search research articles
Search
Showing results (501-510 of 713) with videos related to
Sort By:
Page
of 72
American Journal of Hematology
|
December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma
|
March 27, 2019
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis
Jesus G Berdeja, Michael C Heinrich, Shaker R Dakhil, et al.
British Journal of Haematology
|
December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Stéphane De Botton, Christian Récher, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 21, 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis
James Foran, Farhad Ravandi, William Wierda, et al.
Cancer
|
December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
Susan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood
|
March 17, 2012
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
Farhad Ravandi, Eli Estey, Dan Jones, et al.
Blood
|
August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Deborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.
Cancer
|
December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
William Wierda, Susan O'brien, Stefan Faderl, et al.
American Journal of Hematology
|
October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors
Ahmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.
Page
of 72